It’s estimated that 10% to 15% of people with Parkinson’s have a genetic form of the disease and Sanofi Genzyme is backing a new study to help find those people.
Working with the Parkinson’s Foundation, the effort, called PD GENEration, will provide free genetic testing, either by in-person blood testing at selected sites or by a telemedicine appointment combined with at-home cheek swabs. Follow-up counseling will also be provided to discuss the results. Sanofi will contribute $1 million to the study over the next two years.
The goal of the testing is to identify the specific genetic status of people with Parkinson’s, which can lead to better identification for clinical trials and more personalized therapies.
The Sanofi-backed study will inform participants when “trials become available that are relevant to their genetic status,” James Beck, senior VP and chief scientific officer at the Parkinson’s Foundation, said in an email.
“Because we are banking the DNA to share in a de-identified fashion, we are hopeful that the results obtained through this study will also impact future research to develop improved treatments and personalized medicine for Parkinson’s,” he said.
Today, there are limited genetic testing options for people with Parkinson’s. The tests are often expensive and not covered by insurance, and they use a chip technology that may only identify a few point mutations on the genes linked to Parkinson’s. The main issue, however, is that there is no genetic counseling, Beck said.
The response so far has been positive, with more than 500 people taking part and waiting lists already forming at the foundation’s existing sites, Beck said. The partners plan to add more testing sites at Parkinson’s Foundation Centers of Excellence across the country.
Beck sees the collaboration between Sanofi and the Parkinson’s Foundation as a natural fit.
“Sanofi is a leading pharma company that shares our vision of improving the lives of those affected by PD,” he said, adding that “it made perfect sense to join forces in this project.”
by Sharon Klahr Coey
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”